

# **Biomarkers**

## **Part I: Technologies & Applications**

**A Jain PharmaBiotech Report**



# **Biomarkers**

## **Part 1: Technologies & Applications**

**By**

**Prof. K.K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**June 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor+ 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. The following Jain PharmaBiotech reports are relevant to biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

June 2018

Copyright © 2018 by

Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland

**Tel & Fax:** +4161-6924461  
**Email:** info@pharmabiotech.ch  
**Web site:** <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>27</b>
<b>1. Introduction .....</b>	<b>29</b>
<b>Definitions .....</b>	<b>29</b>
<b>Historical aspects of biomarkers .....</b>	<b>29</b>
<b>Classification of biomarkers .....</b>	<b>30</b>
Biomarker as a response to therapeutic intervention .....	31
Pharmacokinetic/pharmacodynamics biomarkers .....	31
Predictive biomarkers .....	31
Valid biomarkers .....	32
<b>Types of biomarkers .....</b>	<b>33</b>
Genes as biomarkers .....	33
<i>Silent gene mutations</i> .....	33
Epigenetic biomarkers .....	33
Exosomes as biomarkers .....	34
Proteins as biomarkers .....	34
<i>Proteomics</i> .....	35
DNA biomarkers .....	35
Mitochondrial DNA .....	35
<i>Mitochondrial mutations</i> .....	35
RNA biomarkers .....	36
<i>Transcriptomics</i> .....	36
<i>MicroRNAs</i> .....	37
Metabolomics .....	37
Glycomics .....	38
Single nucleotide polymorphisms .....	38
<i>Haplotyping</i> .....	39
Cell biomarkers of disease .....	39
Stem cell biomarkers .....	39
<i>Association of stem cell biomarkers with disease</i> .....	40
<i>Cancer stem cell biomarkers</i> .....	40
<i>Endoglin as a functional biomarker of stem cells</i> .....	40
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i> .....	40
<i>Protein expression profile as biomarker of stem cells</i> .....	41
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i> .....	41
<i>SSEA-4 as biomarker of MSCs</i> .....	41
Gaseous mediators as biomarkers of disease .....	41
Autoantibodies as biomarkers of autoimmune diseases .....	42
Comparison of various types of biomarkers .....	42
<b>Biomarkers and systems biology .....</b>	<b>43</b>
Systems biology approach to biomarker identification .....	44
<b>Relation of biomarkers to other technologies and healthcare .....</b>	<b>44</b>
Biomarkers and translational medicine .....	45
Role of biomarkers in monitoring of diseases .....	46
Limitations of use of biomarkers in healthcare .....	46
<b>2. Technologies for Discovery of Biomarkers .....</b>	<b>47</b>
<b>Introduction .....</b>	<b>47</b>
The ideal biomarker .....	47
<b>Genomic technologies .....</b>	<b>47</b>
Gene expression .....	47
<i>Whole genome expression array</i> .....	48
<i>Gene expression profiling on whole blood samples</i> .....	49
<i>Profiling gene expression patterns of white blood cells</i> .....	49
Tissue microarrays for study of biomarkers .....	49
<b>Technologies for detection of miRNAs as biomarkers .....</b>	<b>50</b>
Microarrays for analysis of miRNA gene expression .....	50
<i>Microarrays vs quantitative PCR for measuring miRNAs</i> .....	51
Point-of-care detection of circulating miRNAs as biomarkers .....	51
<b>Epigenomic technologies .....</b>	<b>51</b>
Discovery of methylation biomarkers .....	52
<b>Proteomic technologies .....</b>	<b>53</b>
2D GE .....	54
ProteoCarta® integrated proteomics discovery platform .....	54
Isotope-coded affinity tags .....	55
Liquid chromatography-MS/MS .....	55
Lucid Proteomics System .....	56
Magnetics beads for protein biomarker discovery .....	56

MASStermind™	56
Combined analysis of protein and nucleic-acid biomarkers	57
Mass spectrometry	57
2D PAGE and mass spectrometry	58
Imaging mass spectrometry	58
MALDI mass spectrometry for biomarker discovery	59
Quantitative tandem MS	59
Single-molecule mass spectrometry using a nanopore	60
Requirements for MS-based proteomic biomarker development	60
Nucleic Acid Programmable Protein Array	60
Protein tomography	61
Protein biochips/microarrays and biomarkers	61
Antibody array/affinity proteomics-based biomarker discovery	61
Detection of biomarkers using peptide array technology	63
ProtoArray®	63
Protein nanobiochip	63
Gene expression microarray data as a source of protein biomarkers	64
Quantification of protein biomarkers	64
CyTOF for quantification of biomarkers	64
Digital protein biomarker measurement	65
Multiple reaction monitoring assays	65
Real-time PCR for quantification of protein biomarkers	65
Search for biomarkers in body fluids	66
Challenges and strategies for discovery of protein biomarkers in plasma	66
Technologies for removal of highly abundant proteins in blood	66
3D structure of CD38 as a biomarker	67
BD™ Free Flow Electrophoresis System	68
Isotope tags for relative and absolute quantification	68
Plasma protein microparticles as biomarkers	68
Proteome partitioning	69
Stable isotope tagging methods	69
Technology to measure both the identity and size of the biomarker	70
Selected reaction monitoring MS	70
Targeted MS for verification of biomarkers	71
Biomarkers in the urinary proteome	72
Peptides as biomarkers of disease	72
Analysis of peptides in bodily fluids	72
Antibody biomarker discovery via evolution of peptides	73
Selected reaction monitoring for validating peptide biomarkers	74
Serum peptidome patterns	74
STSCAPA method for quantitating proteins and peptides in plasma	74
Comparison of proteomic profiling technologies for discovery of biomarkers	75
Verification for interlaboratory reproducibility of protein biomarkers	75
Significance of similar protein biomarkers in different tissues	75
<b>Glycomic technologies</b>	<b>76</b>
Cellular glycomics for discovery of cellular biomarkers	77
<b>Metabolomic technologies</b>	<b>77</b>
Genome-wide association studies for identification of metabolic biomarkers	78
Genetic influences on human blood metabolites	78
Lipid profiling	78
Mass spectrometry for discovery of metabolic biomarkers in plasma	79
Role of metabolomics in biomarker identification and pattern recognition	79
Urinary profiling by capillary electrophoresis	79
Validation of biomarkers in large-scale human metabolomics studies	80
<b>Lipidomics</b>	<b>80</b>
<b>Disease biomarkers in breath</b>	<b>81</b>
Portable breath test for volatile organic compounds	81
Detection of breath biomarkers by sensation technology	81
Detection of breath biomarkers by nanosensors	82
Detection of breath biomarkers optical frequency comb spectroscopy	82
Detection of breath biomarkers by infrared absorption spectroscopy	82
Detection of biomarkers by electronic nose	82
<b>Fluorescent indicators for biomarkers</b>	<b>83</b>
<b>Molecular imaging technologies</b>	<b>83</b>
Computer tomography	83
Magnetic resonance imaging	84
Positron emission tomography	84
Advantages of imaging biomarkers	84
Monitoring in vivo gene expression by molecular imaging	85
Molecular imaging in vivo as a biomarker	85
Challenges and future of molecular imaging	86

<i>Basic research in molecular imaging</i> .....	86
<i>Imaging intracellular NADH as a biomarker of disease</i> .....	86
<i>Devices for molecular imaging</i> .....	87
<i>Imaging biomarkers in clinical trials</i> .....	87
<i>Molecular imaging in clinical practice</i> .....	87
<b>Nuclear magnetic resonance</b> .....	<b>87</b>
Chemical derivatization to enhance biomarker detection by NMR.....	88
Fluxomics by using NMR .....	88
<b>Nanobiotechnology</b> .....	<b>88</b>
Dip Pen Nanolithography .....	89
Nanomaterials for biolabeling .....	89
<i>Quantum dot molecular labels</i> .....	90
<i>Bioconjugated QDs for multiplexed profiling of biomarkers</i> .....	91
<i>Magnetic nanotags for multiply detection of biomarkers</i> .....	91
Nanoparticles for molecular imaging .....	91
Nanoparticles for discovering biomarkers .....	92
Nanoproteomics and biomarkers .....	92
<i>High-field asymmetric waveform ion mobility mass spectrometry</i> .....	92
Nanosensors for measuring biomarkers in blood .....	93
Nanobiochip sensor technique for analysis of oral cancer biomarkers .....	93
Future prospects of application of nanobiotechnology for biomarkers .....	93
<b>Bioinformatics</b> .....	<b>94</b>
Biomarker Workflow Guide .....	94
Analysis of microarray data for selecting useful biomarkers .....	94
Role of bioinformatics in discovery of protein biomarkers .....	94
Role of bioinformatics in detection of cancer biomarkers .....	95
Biomarker databases .....	95
Gene networks as biomarkers.....	96
Role of bioinformatics in integrating various data and biomarker discovery.....	96
<b>Evaluation of biomarker studies</b> .....	<b>97</b>
<b>3. Biomarkers and Molecular Diagnostics</b> .....	<b>99</b>
<b>Introduction</b> .....	<b>99</b>
<b>Molecular diagnostic technologies</b> .....	<b>99</b>
Polymerase chain reaction .....	99
<i>Amplification</i> .....	99
<i>Target selection</i> .....	100
<i>Detection of amplified DNA</i> .....	100
<i>Limitations of PCR</i> .....	100
Real-time PCR systems .....	101
<i>Limitations of real-time PCR</i> .....	101
<i>Future applications of real-time qPCR</i> .....	102
<i>Real-time qPCR for quantification of circulating mtDNA</i> .....	102
Combined PCR-ELISA .....	102
Non-PCR methods .....	103
<i>Linked Linear Amplification</i> .....	103
Transcription mediated amplification .....	103
Rapid analysis of gene expression .....	103
WAVE nucleic acid fragment analysis system .....	104
DNA probes with conjugated minor groove binder .....	104
Rolling circle amplification technology .....	105
<i>Gene-based diagnostics through RCAT</i> .....	105
<i>RCAT-immunodiagnosics</i> .....	106
<i>RCAT-biochips</i> .....	106
<i>RCAT-pharmacogenomics</i> .....	106
Circle-to-circle amplification .....	106
<b>Biomarkers and high throughput molecular screening</b> .....	<b>107</b>
<b>Detection and expression profiling of miRNA</b> .....	<b>107</b>
Real-time PCR for expression profiling of miRNAs.....	107
Use of LNA to explore miRNA.....	108
Microarrays for analysis of miRNA gene expression .....	108
<b>Devices for biomarkers</b> .....	<b>108</b>
Biochips and microarrays .....	108
<i>Applications of biochips/microarrays</i> .....	109
<i>Role of biochip/microarrays in discovery of biomarkers</i> .....	109
Biosensors for biomarkers .....	110
<i>Biosensor for analysis of sweat biomarkers</i> .....	110
<b>4. Biomarkers for Drug Discovery &amp; Development</b> .....	<b>113</b>
<b>Introduction</b> .....	<b>113</b>
<b>Biomarker technologies for drug discovery</b> .....	<b>113</b>

Proteomics-based biomarkers for drug discovery .....	113
Chemoproteomics .....	114
<i>Activity-based chemical proteomics</i> .....	114
Transcriptomics for drug discovery .....	114
Metabolomics for drug discovery .....	115
<b>Biomarkers and drug safety .....</b>	<b>115</b>
Biomarkers of adverse drug reactions .....	115
Applications of biomarkers in drug safety studies .....	116
Genomic technologies for toxicology biomarkers .....	116
Proteomic technologies for toxicology biomarkers .....	117
Metabonomic technologies for toxicology biomarkers .....	117
Integration of genomic and metabonomic data to develop toxicity biomarkers .....	117
Toxicology studies based on biomarkers .....	118
<i>Biomarker of genotoxicity</i> .....	119
<i>Biomarkers of hepatotoxicity</i> .....	119
<i>Biomarkers of nephrotoxicity</i> .....	120
<i>Cardiotoxicity</i> .....	122
<i>Neurotoxicity</i> .....	122
<b>Applications of biomarkers for drug development.....</b>	<b>123</b>
Application of metabolomics/metabolomics for drug development .....	123
Application of biomarkers by the pharmaceutical companies .....	124
Biomarkers in clinical trials.....	125
<i>NIH recommendations on the use of biomarkers in clinical trials</i> .....	125
<i>Advantages of biomarkers for drug development.....</i>	127
<i>Limitations and problems with use of biomarkers in clinical trials</i> .....	127
Development of static and dynamic biomarkers .....	128
Molecular imaging as a biomarker in drug development .....	128
<i>Molecular imaging in preclinical studies</i> .....	128
<i>Molecular imaging in clinical trials</i> .....	129
<i>Prospects of molecular imaging in drug discovery and development</i> .....	130
Pharmacogenomic biomarker information in drug labels.....	130
Role of biomarkers in vaccine development .....	131
Role of biomarkers in relation to stage of drug discovery and development .....	131
Role of pharmacokinetic/pharmacodynamic biomarkers in drug development .....	132
Role of biomarkers for drug development in cardiovascular disorders .....	133
Role of biomarkers for drug development in neurological disorders.....	133
Significance of biomarkers in drug development .....	133
<b>Organizations &amp; resources for biomarker-based drug development.....</b>	<b>134</b>
Biomarker Alliance .....	134
Biomarkers Consortium .....	134
Molecular Libraries and Imaging Roadmap of NIH .....	135
Rare Diseases Clinical Research Consortia .....	136
<b>Future of biomarker-based drug development .....</b>	<b>136</b>
<b>5. Role of Biomarkers in Healthcare.....</b>	<b>139</b>
<b>Introduction.....</b>	<b>139</b>
<b>Biomarkers of inflammation.....</b>	<b>140</b>
ESR and CRP as biomarkers of inflammation .....	140
Metabolic biomarkers of inflammation.....	141
YKL-40 as a biomarker inflammation and predictor of mortality .....	141
<b>Biomarkers of allergic disorders .....</b>	<b>141</b>
<b>Biomarkers of oxidative stress.....</b>	<b>142</b>
1,4-dihydroxynonane-mercapturic acid .....	142
Oxidized phospholipids .....	142
Oxidative DNA damage .....	143
Proteins as biomarkers of oxidative stress in diseases.....	143
Testing for oxidative stress .....	143
<b>Biomarkers of hypoxia .....</b>	<b>144</b>
Pathophysiology of hypoxia .....	144
Hypoxia inducible factor as biomarker of hypoxia and response to oxygenation .....	144
Identification of hypoxia biomarkers from exhaled breath .....	144
Metabolic biomarkers of hypoxia .....	145
<b>Biomarkers of liver disease.....</b>	<b>145</b>
Breath biomarkers of liver disease .....	145
Biomarkers of liver injury.....	145
Fibrosis and cirrhosis of liver .....	146
FibroMax.....	146
Hepatic encephalopathy .....	146
miRNA biomarkers of liver disease .....	147
Viral hepatitis B and C .....	147
<i>Biomarkers of hepatitis C</i> .....	147



<i>Biomarkers of hepatitis B</i> .....	148
<b>Biomarkers of pancreatitis</b> .....	<b>148</b>
<b>Biomarkers of renal disease</b> .....	<b>149</b>
Biomarkers of lupus nephritis .....	149
Biomarkers of diabetic nephropathy .....	150
Cystatin C as biomarker of glomerular filtration rate (GFR) .....	150
Estimated GFR and albuminuria as biomarkers of chronic kidney disease .....	150
Proteomic biomarkers of acute kidney injury .....	151
Symmetric dimethylarginine as biomarker of chronic kidney disease in dogs .....	151
Troponin-T as a biomarker for predicting end-stage renal disease .....	151
<b>Biomarkers in pediatrics</b> .....	<b>151</b>
Pediatric critical care .....	151
Biomarkers of acute kidney injury in children .....	152
<b>Biomarkers of miscellaneous disorders</b> .....	<b>152</b>
Biomarkers of acid-base disorders in acute care setting .....	152
Biomarkers of carbon monoxide poisoning .....	152
Biomarkers of Castleman disease.....	153
Biomarkers of erectile dysfunction.....	153
Biomarkers of fever.....	154
Biomarkers of heat stroke .....	154
Biomarkers of hyponatremia.....	154
Biomarkers of inflammatory bowel disease .....	155
Biomarkers of radiation injury .....	156
Biomarkers for prediction of all-cause mortality .....	156
Biomarkers common to multiple diseases.....	156
Nasal nitric oxide as a biomarker of response to rhinosinusitis therapy .....	157
<b>Biomarkers of gene-environmental interactions in human disease</b> .....	<b>158</b>
<b>Application of biomarkers in animal health</b> .....	<b>158</b>
<b>6. Biomarkers in Metabolic Disorders</b> .....	<b>161</b>
Biomarkers of acute intermittent porphyria .....	161
Liver X receptors.....	161
Biomarkers of diabetes mellitus .....	161
<i><math>\beta</math>-cell function as biomarker of diabetes</i> .....	163
<i>Biomarkers of hyperglycemia</i> .....	163
<i>Biomarkers of diabetes-associated oxidative stress</i> .....	163
<i>Biomarkers of inflammation associated with diabetes</i> .....	163
<i>Biomarkers of renal complications in diabetes mellitus type 2</i> .....	164
<i>Biomarkers of diabetes</i> .....	164
<i>Biomarkers of prediabetes</i> .....	164
<i>Biomarkers of insulin resistance</i> .....	164
<i>Glycosylated hemoglobin in diabetes mellitus</i> .....	165
<i>Glycated albumin as a biomarker of diabetes mellitus</i> .....	165
<i>Low C-peptide as a biomarker of complications of diabetes type 1</i> .....	165
<i>Personalized management of diabetes mellitus based on biomarkers</i> .....	166
Biomarkers of metabolic syndrome.....	166
<i>Adiponectin</i> .....	166
<i>Cystatin C</i> .....	167
<i>Human plasma lipidome</i> .....	167
<i>Neurotensin as biomarker of obesity</i> .....	168
<b>7. Biomarkers in Immune Disorders</b> .....	<b>171</b>
<b>Introduction</b> .....	<b>171</b>
<b>Biomarkers relevant to organ transplantation</b> .....	<b>171</b>
Biomarkers of graft versus host disease .....	171
Biomarkers of renal allograft failure.....	172
Biomarkers of renal transplant tolerance .....	173
Biomarkers of lung transplant rejection.....	174
Biomarkers of GVHD following transplantation of hematopoietic cells.....	174
Plasma biomarkers of response to therapy of GVHD .....	174
<b>Systemic lupus erythematosus</b> .....	<b>175</b>
Adiponectin as biomarker of SLE .....	175
Current management and need for biomarkers of SLE .....	175
Role of collaborative efforts and databases of SLE biomarkers .....	176
C4d-bearing reticulocytes .....	176
CB-CAPS.....	176
Epigenetic biomarkers of SLE .....	176
Genetic loci of SLE .....	177
HMGB1 .....	177
<b>Biomarkers of systemic sclerosis</b> .....	<b>177</b>
<b>Biomarkers of Sjögren syndrome</b> .....	<b>178</b>

<b>8. Biomarkers of Musculoskeletal Disorders .....</b>	<b>181</b>
<b>Introduction.....</b>	<b>181</b>
<b>Muscle disorders .....</b>	<b>181</b>
Biomarkers of muscle fatigue during exercise .....	181
Biomarkers of mitochondrial content in skeletal muscle .....	181
Idiopathic inflammatory myopathies .....	182
<b>Rheumatoid arthritis.....</b>	<b>182</b>
Assays for biomarkers of RA .....	183
Biomarkers for personalizing therapy of rheumatoid arthritis .....	183
Circulating cytokines in RA .....	184
Epigenetic biomarkers of rheumatoid arthritis .....	184
miRNA biomarkers in RA .....	184
Serum CRP in RA .....	185
<b>Biomarkers of spondylarthritis.....</b>	<b>185</b>
Biomarkers of axial spondyloarthritis .....	186
Biomarkers of psoriatic arthritis .....	186
<b>Osteoarthritis.....</b>	<b>186</b>
Molecular pathophysiology of OA.....	187
Biomarkers of osteoarthritis .....	187
Assays for biomarkers of OA.....	188
Biomarkers of OA.....	188
Concluding remarks and future prospects of biomarkers of OA.....	189
<b>Biomarkers of osteoporosis .....</b>	<b>189</b>
Assays for detection of biomarkers of osteoporosis.....	189
Bone imaging with quantitative CT and MRI .....	190
Circulating miRNAs as biomarkers of osteoporosis.....	190
Dual x-ray absorptiometry .....	191
Utility of biomarkers of osteoporosis.....	191
<b>Biomarkers of osteonecrosis .....</b>	<b>191</b>
Osteonecrosis in Gaucher's disease .....	191
<b>9. Biomarkers of Infectious Diseases.....</b>	<b>193</b>
<b>Introduction.....</b>	<b>193</b>
<b>Technologies for discovery of biomarkers of infection .....</b>	<b>193</b>
Chemokines as biomarkers of infection .....	193
Endotoxin as biomarker of infection.....	193
Proteomics for discovering biomarkers of infections.....	193
Soluble urokinase plasminogen activator receptor .....	194
<b>Sepsis .....</b>	<b>194</b>
Biomarkers of sepsis .....	195
<i>Circulating CPS-1 as biomarkers of organ damage in sepsis.....</i>	<i>196</i>
<i>CoQ10 level reduction in septic shock .....</i>	<i>196</i>
<i>Multibiomarker-based outcome risk stratification of septic shock .....</i>	<i>197</i>
<i>Nitric oxide as a biomarker of sepsis.....</i>	<i>197</i>
<i>SuPAR as a biomarker of sepsis .....</i>	<i>197</i>
Systemic inflammatory response syndrome .....	198
<b>Tuberculosis .....</b>	<b>198</b>
Conventional diagnosis of tuberculosis.....	199
Molecular diagnostics for tuberculosis .....	199
Biomarkers for tuberculosis .....	199
Biomarkers of pulmonary tuberculosis in the breath .....	200
<b>Biomarkers of viral infections .....</b>	<b>200</b>
Viral hepatitis .....	200
Biomarkers of SARS .....	202
Biomarkers of HIV .....	203
<b>Biomarkers in parasitic infections.....</b>	<b>204</b>
Role of biomarkers in malaria .....	204
Identification of biomarkers in Schistosomiasis infections.....	204
<b>Diagnostic &amp; therapeutic applications of biomarkers of infections .....</b>	<b>205</b>
Biomarkers to discriminate bacterial from nonbacterial respiratory infections.....	205
Procalcitonin as a guide to antibiotic therapy in infections .....	205
<b>10. Biomarkers of Genetic Disorders.....</b>	<b>207</b>
<b>Introduction.....</b>	<b>207</b>
<b>Biomarkers of Down's syndrome .....</b>	<b>207</b>
<b>Biomarkers of muscular dystrophy .....</b>	<b>207</b>
<b>Biomarkers of phenylketonuria.....</b>	<b>208</b>
<b>Genetic biomarkers of psoriasis .....</b>	<b>208</b>
<b>Biomarkers of lysosomal storage disorders .....</b>	<b>209</b>
Biomarkers of Niemann-Pick disease .....	209
<i>Bile acids as biomarkers for the early diagnosis of NPd .....</i>	<i>209</i>

<i>Cholesterol oxidation products as biomarkers of NPD</i> .....	209
Biomarkers of mucopolysaccharidoses .....	210
<i>Proteomic technologies for biomarkers of MPS</i> .....	210
<i>Glycan-based biomarkers for MPS</i> .....	211
<i>Biomarkers of LSD</i> .....	211
<i>Prenatal diagnosis of LSD</i> .....	211
Biomarkers of Fabry's disease .....	212
<b>11. Biomarkers of Aging .....</b>	<b>213</b>
<b>Introduction</b> .....	<b>213</b>
<b>Biomarkers of biological age</b> .....	<b>214</b>
Gene variants as determinants of biological age.....	215
Gene expression profiles for calculating transcriptomic age .....	215
<b>Biomarkers of healthy aging</b> .....	<b>215</b>
<b>Biomarkers of longevity</b> .....	<b>216</b>
Effect of calorie restriction on biomarkers of longevity .....	216
Healthy aging index .....	216
Low serum thyroid hormone level as biomarker of longevity .....	216
<b>Biomarkers as predictors of mortality with aging</b> .....	<b>217</b>
Genetic biomarkers of aging.....	217
Genetic signatures of longevity .....	217
<b>Metabolomic biomarkers of aging</b> .....	<b>218</b>
<b>Mitochondrial mutations as biomarkers of aging</b> .....	<b>218</b>
<b>Oxidative biomarkers of aging</b> .....	<b>218</b>
<b>Molecular diagnostics and biomarkers of age-related diseases</b> .....	<b>219</b>
<b>Protein biomarkers of aging</b> .....	<b>219</b>
Carbamylated proteins as biomarkers of aging.....	219
Proteomic biomarkers of muscle aging.....	220
Role of humanin in age-related diseases .....	220
<b>Role of bioinformatics in search for biomarkers of aging</b> .....	<b>220</b>
<b>Aging biomarkers in a genetically homogeneous population</b> .....	<b>220</b>
<b>Telomere attrition as aging biomarker</b> .....	<b>221</b>
<b>12. Nutritional Biomarkers.....</b>	<b>223</b>
<b>Introduction</b> .....	<b>223</b>
<b>Biomarkers of Nutrition for Development project</b> .....	<b>223</b>
<b>Biomarkers in nutritional epidemiology</b> .....	<b>223</b>
<b>Biomarkers of nutritional status</b> .....	<b>224</b>
Ferritin as biomarker of nutritional status.....	224
Folate biomarkers related to nutritional health status .....	225
Iodine as biomarker of nutritional status .....	225
Zinc as a biomarker of nutritional status .....	226
<b>Biomarkers of branched chain amino acid status</b> .....	<b>226</b>
<b>Biomarkers of caloric restriction</b> .....	<b>226</b>
<b>Biomarkers of malnutrition</b> .....	<b>226</b>
Maternal nutrition during early pregnancy causes epigenetic changes .....	227
<b>Proteomic biomarkers and nutrition</b> .....	<b>227</b>
<b>Vitamin deficiency as biomarker of disease</b> .....	<b>227</b>
Vitamin A biomarkers .....	227
Vitamin B12 deficiency .....	228
Vitamin D deficiency as a biomarker of disease .....	229
<b>Role of biomarkers in the development of personalized nutrition</b> .....	<b>229</b>
<b>13. Biomarkers of Cancer.....</b>	<b>231</b>
<b>Introduction</b> .....	<b>231</b>
The ideal biomarker for cancer .....	231
Biomarkers and hallmarks of cancer .....	232
Single vs multiple biomarkers of cancer .....	232
<b>Types of cancer biomarkers</b> .....	<b>233</b>
miRNAs as biomarkers in cancer .....	233
<i>Diagnostic value of miRNA in cancer</i> .....	235
Biomarkers of epigenetic gene silencing in cancer .....	235
<i>5-hydroxymethylcytosine as a biomarker of cancer</i> .....	236
Carcinoembryonic antigen .....	236
Circulating cancer biomarkers.....	236
<i>Circulating tumor cells as cancer biomarkers</i> .....	236
<i>Circulating nucleic acids as potential biomarkers of cancer</i> .....	237
<i>Circulating exosomes and microvesicles as biomarkers of cancer</i> .....	237
<i>Circulating miRNAs for cancer detection</i> .....	238
DNA repair biomarkers .....	238
HER3 as biomarker of cancer .....	238

Immunologic and inflammation biomarkers of cancer .....	238
Metastatic cancer biomarkers .....	239
<b>Molecular diagnostic techniques for cancer .....</b>	<b>239</b>
<b>Technologies for detection of cancer biomarkers .....</b>	<b>241</b>
Genomic technologies for cancer biomarkers .....	241
<i>Biomarkers of PTEN tumor suppressor gene status</i> .....	241
<i>Cold-PCR</i> .....	241
<i>ddPCR for detection of cancer biomarkers in cell free plasma DNA</i> .....	242
<i>Digital karyotyping for cancer biomarkers</i> .....	242
<i>Genome analysis at the molecular level</i> .....	242
<i>KRAS as a biomarker of cancer</i> .....	243
<i>LigAmp for detection of gene mutations in cancer</i> .....	243
<i>Mitochondrial DNA as a cancer biomarker</i> .....	243
<i>Next generation sequencing for detection of cancer biomarkers</i> .....	244
<i>Telomerase as a biomarker of cancer</i> .....	245
Tissue microarrays for study of cancer biomarkers .....	245
Molecular fingerprinting of cancer .....	246
Proteomic technologies for detecting biomarkers of cancer .....	246
2D PAGE .....	247
<i>Antibody-based detection of protein biomarkers</i> .....	247
<i>Aptamer-based molecular probes for cancer biomarker discovery</i> .....	248
<i>Biomarkers of protein-drug interactions in cancer</i> .....	248
<i>Cancer immunomics to identify autoantibody signatures</i> .....	249
<i>Desorption electrospray ionization for detection of cancer biomarkers</i> .....	249
<i>Detection of circulating nucleosomes in serum of cancer patients</i> .....	249
<i>Detection of tumor biomarkers with ProteinChip technology</i> .....	250
<i>Glycoprotein biomarkers of cancer</i> .....	250
<i>HER-2/neu oncoprotein as biomarkers for cancer</i> .....	250
<i>Humoral proteomics</i> .....	251
<i>Laser capture microdissection</i> .....	251
<i>Membrane-type serine protease-1</i> .....	251
<i>Proteomic analysis of cancer cell mitochondria</i> .....	252
<i>Proteomic technologies for detection of autoimmune biomarkers</i> .....	252
SELDI-TOF MS .....	253
<i>Serum proteome analysis for early detection of cancer</i> .....	253
<i>Synthetic biomarker-based POC diagnostic for cancer</i> .....	253
<i>Triple-quadrupole MS for detection of mutant proteins</i> .....	253
<i>Targeted MS for validation of cancer biomarkers in plasma</i> .....	254
<i>Tissue proteomics for discovery of cancer biomarkers</i> .....	254
<i>VeraTag system for cancer biomarkers</i> .....	254
Metabolomic biomarkers of cancer .....	254
<i>Magnetic resonance for detecting metabolomics biomarkers of cancer</i> .....	255
<i>Choline phospholipid biomarkers of cancer</i> .....	255
<i>Hypoxia-inducible factor-1</i> .....	255
<i>Detection of drug resistance in cancer by metabolic profiling</i> .....	256
<i>Plasma free amino acids profiling in cancer</i> .....	256
<i>Urinary metabolomic biomarkers of cancer</i> .....	257
Epitomics for the early detection of cancer .....	257
Epigenetic biomarkers of cancer .....	257
<i>Detection of biomarkers of DNA methylation</i> .....	258
<i>Epigenomics Marker Machine for DNA methylation biomarkers</i> .....	259
<i>Histone deacetylase</i> .....	259
<i>MDSca<sup>TM</sup> microarray technology</i> .....	259
<i>Mucins as epigenetic biomarkers in epithelial cancers</i> .....	260
<i>PCR with bisulfite for detecting DNA methylation biomarkers in cancer</i> .....	260
<i>Detection of methylated DNA in serum and urine</i> .....	261
<i>Integrated platform for genetic and epigenetic analysis</i> .....	261
Nanobiotechnology for early detection of cancer to improve treatment .....	262
<i>Aptasensor for electrochemical detection of exosomes</i> .....	262
<i>Nanovesicles for detection of cancer biomarkers</i> .....	262
<i>Nanowire biosensors for detection of cancer biomarkers</i> .....	263
<i>NP-peptide complexes for detection of cancer biomarkers in urine</i> .....	264
Ultrasound radiation to enhance release of a tumor biomarker .....	264
In vivo imaging of cancer biomarkers .....	264
<i>Computer tomography</i> .....	264
<i>Optical systems for in vivo molecular imaging of cancer</i> .....	265
<i>Positron emission tomography</i> .....	265
<i>Imaging of tumor oxygenation and microvascular permeability by MRI</i> .....	265
<i>Xenon-enhanced MRI</i> .....	266
Kallikrein gene family and cancer biomarkers .....	266
Detection of CTCs as biomarkers of cancer .....	266

<b>Applications of cancer biomarkers .....</b>	<b>267</b>
Use of biomarkers for cancer classification .....	267
<i>Cancer classification using microarrays .....</i>	267
<i>Proteomic classification of cancer .....</i>	268
Use of biomarkers for early detection of cancer .....	268
Applications of biomarkers for cancer diagnosis .....	268
<i>Methylated DNA sequences as cancer biomarkers .....</i>	268
<i>MicroRNA expression profiling for diagnosis of human cancers .....</i>	269
<i>MUC4 as a diagnostic biomarker in cancer .....</i>	270
Applications of biomarkers for cancer diagnosis and therapy .....	270
<i>ARTS as a biomarker as well as a basis of anticancer drugs .....</i>	271
<i>Asparagine synthetase as biomarker for therapy with L-asparaginase .....</i>	272
<i>Peptide-based agents for targeting cancer biomarkers .....</i>	272
<i>PI3K mutations as a biomarker for use as a companion diagnostic .....</i>	272
Biomarkers for assessing efficacy of cancer therapy .....	273
<i>ERCC1-XPF expression as a biomarker of response to chemotherapy .....</i>	273
<i>P53 expression level as biomarker of efficacy of cancer gene therapy .....</i>	273
Biomarkers of angiogenesis for developing antiangiogenic therapy .....	273
<i>Biomarkers of response to antiangiogenic agents .....</i>	273
<i>Circulating endothelial cells as targets for antiangiogenic drugs .....</i>	274
<i>Imaging biomarkers for evaluation of antiangiogenic agents .....</i>	274
<i>Tumor endothelial biomarkers .....</i>	275
<i>VEGF signaling inhibitors as biomarkers .....</i>	275
<i>VEGF-PET imaging for analysis of angiogenic changes within a tumor .....</i>	275
Biomarkers of prognosis in cancer treatment .....	276
Biomarkers for monitoring cancer therapy .....	276
Biomarkers of drug resistance in cancer .....	276
<i>A systems approach to biomarkers of innate drug resistance .....</i>	277
<i>Epithelial membrane protein-1 as a biomarker of gefitinib resistance .....</i>	277
<i>Methylation biomarkers of drug resistance in cancer .....</i>	277
<i>STAT3 and resistance to cisplatin .....</i>	278
Biomarkers of radiation therapy for cancer .....	278
<b>Role of biomarkers in drug development in oncology .....</b>	<b>278</b>
Biomarker-based approval of an anticancer drug regardless of site .....	279
Biomarkers in plucked hair for assessing cancer therapy .....	280
Met receptors as targets for anticancer drugs .....	280
Molecular imaging of tumor as a guide to drug development .....	280
<i>Use of PET and SPECT to assess response to anticancer drugs .....</i>	281
<i>Use of MRI to assess response to anticancer drugs .....</i>	281
Role of biomarkers in phase I clinical trials of anticancer drugs .....	282
Safety biomarkers in oncology studies .....	282
<b>Biomarkers according to organ/type of cancer .....</b>	<b>282</b>
Bladder cancer biomarkers .....	283
<i>Detection of FGFR3 mutations in urine for diagnosis of bladder cancer .....</i>	283
<i>NMP22 BladderChek .....</i>	283
<i>Urinary telomerase as biomarker for detection of bladder cancer .....</i>	283
<i>Concluding remarks about biomarkers of urinary cancer .....</i>	283
Brain tumor biomarkers .....	284
<i>14-3-3zeta positive expression as a prognostic biomarker for GBM .....</i>	284
<i>ALDH1A3 as a biomarker of GBM .....</i>	285
<i>Biomarkers to predict response to EGFR inhibitors .....</i>	285
<i>Biomarkers for predicting recurrence of meningiomas .....</i>	285
<i>CD133 as biomarker of resistance to radiotherapy .....</i>	285
<i>Circulating microvesicles as biomarkers .....</i>	286
<i>CSF attractin as a biomarker of malignant astrocytoma .....</i>	286
<i>ELTD1 as a biomarker of gliomas .....</i>	286
<i>Methylation profiling of brain tumors .....</i>	286
<i>Metabolite biomarkers of brain tumors .....</i>	288
<i>miRNAs as biomarkers of brain tumors .....</i>	288
<i>MRI biomarker for response of brain tumor to therapy .....</i>	289
<i>Multigene predictor of outcome in GBM .....</i>	289
<i>Neuroimaging biomarkers combined with DNA microarray analysis .....</i>	289
<i>Proteomic analysis of CSF for identification of biomarkers for gliomas .....</i>	289
<i>Receptor protein tyrosine phosphatase <math>\beta</math> as biomarker of gliomas .....</i>	290
<i>Serum protein fingerprinting .....</i>	290
<i>VEGF-R2 as biomarker of angiogenesis in brain tumors .....</i>	290
<i>Future prospects of biomarkers of malignant gliomas .....</i>	290
Bone tumor biomarkers .....	291
<i>Cytogenetics for the study of bone and soft tissue tumors .....</i>	291
<i>Biomarkers of Ewing's tumors .....</i>	291
<i>Role of biomarkers in the diagnosis of bone tumors .....</i>	291

Breast cancer biomarkers.....	292
Autoantibody biomarkers of breast cancer.....	293
Biomarkers of breast cancer in breath .....	294
Biomarkers for breast cancer in nipple aspiration fluid .....	294
Circulating tumor DNA as biomarker of breast cancer .....	294
Circulating exosomes as biomarkers of breast cancer .....	294
Flow cytometry for quantification of biomarker expression patterns.....	295
Plasma proteomics for biomarkers of breast cancer .....	295
Quantitative realtime PCR assays for biomarker validation .....	295
Cdk6 as a biomarker of breast cancer .....	296
Centromere protein-F.....	296
Carbonic anhydrase IX.....	297
COX-2 as a biomarker of breast cancer .....	297
G88 as a biomarker of progression of ER+ breast cancer .....	297
Glycomic biomarkers of breast cancer.....	297
HER-2/neu oncoprotein.....	298
High mobility group protein A2 .....	299
Hypermethylated genes as biomarkers of metastatic breast cancer .....	299
Lipocalin 2 as biomarker of breast cancer progression .....	299
Long intervening non-coding RNAs .....	300
Mammaglobin .....	300
miRNA biomarkers of breast cancer .....	300
p27 expression as biomarker for survival after chemotherapy.....	301
Podocalyxin .....	302
Pronurotensin and Proenkephalin.....	302
Proliferating cell nuclear antigen .....	302
Protein kinase C as a predictive biomarker of metastatic breast cancer .....	302
Retinoblastoma tumor suppressor gene as a biomarker .....	303
Riboflavin carrier protein.....	303
Risk of invasive cancer after diagnosis of ductal carcinoma in situ .....	303
Serum CA 15-3 as biomarker of prognosis in advanced breast cancer .....	304
Stage-specific embryonic antigen-3.....	304
Suppressor of deltex protein.....	304
Tumor microenvironment as biomarker of metastasis in breast cancer.....	304
Type III TGF- $\beta$ receptor as regulator of cancer progression.....	305
Diagnostic tests based on breast cancer genes .....	305
Prognostic role of breast cancer genes .....	306
Protein biomarkers for breast cancer prevention .....	307
Biomarkers to evaluate efficacy of chemoprevention.....	307
Biomarkers of response to chemotherapy of breast cancer .....	307
Biomarker-guided decisions for breast cancer therapy .....	308
Concluding remarks and future prospects of breast cancer biomarkers.....	308
Cervical cancer biomarkers .....	308
Gastrointestinal cancer biomarkers.....	309
Esophageal cancer biomarkers.....	310
Gastric cancer biomarkers.....	310
Colorectal cancer biomarkers.....	311
Head and neck cancer .....	317
Leukemia biomarkers .....	319
Chromosome translocations in leukemias .....	319
DNA methylation biomarkers in leukemia .....	319
Gene mutations as biomarkers in leukemia .....	320
Molecular diagnostic techniques for leukemia.....	320
Proteomic technologies for discovering biomarkers of leukemia.....	321
Biomarkers of chronic lymphocytic leukemia.....	321
Biomarkers of chronic myeloid leukemia .....	322
Biomarkers of drug resistance in leukemia .....	322
Biomarkers of myelodysplastic syndromes.....	322
Lymphoma biomarkers .....	323
Liver cancer biomarkers.....	323
Biomarkers indicating lower risk of HCC in coffee drinkers.....	324
Metabonomic profiles discriminate HCC from liver cirrhosis.....	324
Urinary biomarkers of HCC.....	324
Lung cancer biomarkers.....	325
Autoantibodies as biomarkers in lung cancer .....	326
Biomarkers associated with neuroendocrine differentiation in NSCLC .....	326
Biomarkers of chronic inflammation in lung cancer .....	327
Biomarkers for predicting sensitivity to chemotherapy in lung cancer.....	327
Biomarkers for prediction of sensitivity to EGFR inhibitors .....	328
CTCs as biomarkers of lung cancer .....	329
Genomic biomarkers of lung cancer.....	329

<i>Methylation biomarkers of lung cancer</i> .....	330
<i>miRNA biomarkers in lung cancer</i> .....	330
<i>Noninvasive detection of lung cancer using exhaled breath</i> .....	331
<i>Serum protein biomarkers of lung cancer</i> .....	331
<i>tNOX as biomarker of lung cancer</i> .....	332
<i>Tumor-derived DNA and RNA markers in blood</i> .....	332
<i>Volatile organic compounds in the exhaled breath</i> .....	333
Malignant pleural mesothelioma .....	333
Melanoma biomarkers .....	334
Nasopharyngeal carcinoma biomarkers .....	335
<i>Proteomic biomarkers of nasopharyngeal cancer</i> .....	336
<i>miRNA biomarkers of nasopharyngeal carcinoma</i> .....	336
Oral cancer biomarkers .....	337
Ovarian cancer biomarkers .....	337
<i>3D microfluidic platform to assess multiple ovarian cancer biomarkers</i> .....	338
<i>CA125 as biomarker of ovarian cancer</i> .....	338
<i>Epitomics approach for ovarian cancer biomarkers in serum</i> .....	339
<i>FGF18 as a biomarker in ovarian cancer</i> .....	339
<i>Gene expression studies in ovarian cancer</i> .....	339
<i>HE4 protein in urine as a biomarker for ovarian cancer</i> .....	340
<i>Hematogenous metastasis of ovarian cancer</i> .....	340
<i>HtrA1 as a biomarker of response to chemotherapy in ovarian cancer</i> .....	340
<i>Mutation of genes in ovarian cancer</i> .....	341
<i>Serum biomarkers of ovarian cancer prognosis</i> .....	341
<i>TIM-3 as a biomarker of ovarian cancer</i> .....	341
<i>Multiplex assays for biomarkers of ovarian cancer</i> .....	342
<i>Concluding remarks on biomarker-based tests of ovarian cancer</i> .....	342
Pancreatic cancer biomarkers .....	343
<i>Discovery and validation of pancreatic cancer biomarkers</i> .....	344
<i>Cancer stem cells as biomarkers of pancreatic cancer</i> .....	344
<i>Circulating exosomes as biomarkers of pancreatic cancer</i> .....	344
<i>Histone modifications used as biomarkers in pancreatic cancer</i> .....	344
<i>miRNA biomarkers of pancreatic cancer</i> .....	345
<i>Macrophage inhibitory cytokine-1 as biomarker of pancreatic cancer</i> .....	346
<i>Proteomic biomarkers of pancreatic cancer</i> .....	346
<i>Concluding remarks on biomarkers of pancreatic cancer</i> .....	346
Parathyroid cancer biomarkers .....	347
Peripheral nerve tumors .....	347
<i>Biomarkers of neurofibromatosis</i> .....	347
Prostate cancer .....	348
<i>Adipose tissue-derived biomarkers of obesity-related prostate cancer</i> .....	348
<i>B7-H3 as biomarker of prostate cancer</i> .....	349
<i>Cancer genetics-guided biomarker signatures of prostate cancer</i> .....	349
<i>Detection of prostate cancer biomarkers in urine</i> .....	349
<i>Detection of prostatic intraepithelial neoplasia</i> .....	350
<i>Epigenetic biomarkers of prostate cancer</i> .....	350
<i>Exosomes as biomarkers of prostate cancer</i> .....	351
<i>Gene expression analysis of prostate cancer</i> .....	351
<i>Genetic biomarkers of prostate cancer</i> .....	352
<i>Identification of prostate cancer mRNA biomarkers</i> .....	352
<i>Kallikreins as biomarkers of prostate cancer</i> .....	353
<i>LCM for diagnosis of prostate cancer</i> .....	353
<i>Microarray for diagnosis of prostate cancer</i> .....	354
<i>miRNA biomarkers of prostate cancer</i> .....	354
<i>Prostate cancer biomarkers in semen</i> .....	355
<i>PSA as biomarker of prostate cancer</i> .....	355
<i>ProPSA as biomarker of prostate cancer</i> .....	356
<i>Prostate Health Index</i> .....	356
<i>Prostasomes in blood as biomarker of prostate cancer</i> .....	356
<i>PSMA as biomarker of prostate cancer</i> .....	357
<i>Sarcosine as a metabolic biomarker of prostate cancer</i> .....	357
<i>Silenced CDH13 gene as a biomarker of cancer</i> .....	357
<i>Serum-protein fingerprinting</i> .....	357
<i>Concluding remarks on biomarkers of prostate cancer</i> .....	358
Renal cancer biomarkers .....	358
<i>Gene expression profile of RCC for biomarkers</i> .....	358
<i>miRNA biomarkers of renal cancer</i> .....	359
<i>Use of proteomics for detection of RCC biomarkers</i> .....	359
<i>Use of RCC biomarkers for prognosis and therapy</i> .....	359
Thyroid cancer biomarkers .....	360
<i>Detection of BRAF mutation</i> .....	360

Gene expression biomarkers of thyroid cancer .....	361
miRNA biomarkers of thyroid cancer .....	361
Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer .....	361
<b>Role of the NCI in cancer biomarkers .....</b>	<b>362</b>
<b>Future prospects for cancer biomarkers .....</b>	<b>363</b>
Cancer biomarker research at academic institutions .....	363
Future challenges in the discovery of cancer biomarkers .....	363

#### **14. Biomarkers of Disorders of the Nervous System ..... 365**

<b>Introduction.....</b>	<b>365</b>
<b>Discovery of biomarkers for neurological disorders .....</b>	<b>365</b>
Antibodies as biomarkers in disorders of the nervous system.....	366
Biomarker identification in the CSF using proteomics.....	367
Biomarker identification in the CSF using lipidomics .....	367
Cerebral microdialysis for the study of biomarkers of cerebral metabolism .....	367
Brain imaging for detection of biomarkers .....	368
Data mining for biomarkers of neurological disorders.....	368
Detection of protein biomarkers of CNS disorders in the blood .....	369
Genomic technologies for study of biomarkers of neurological disorders.....	369
<b>Biomarkers of neuroinflammation.....</b>	<b>369</b>
<b>Biomarkers of neural regeneration .....</b>	<b>370</b>
<b>Biomarkers of disruption of blood-brain barrier.....</b>	<b>370</b>
<b>Biomarkers of neurotoxicity.....</b>	<b>371</b>
Glial fibrillary acidic protein as biomarker of neurotoxicity .....	371
Single-stranded DNA as a biomarker of neuronal apoptosis .....	372
<b>Biomarkers of neurogenetic disorders .....</b>	<b>372</b>
Charcot-Marie Tooth disease .....	372
Duchenne and Becker muscular dystrophy .....	373
Early-onset torsion dystonia .....	374
Fragile X syndrome .....	374
Genetic neurotransmitter disorders .....	375
Hereditary neuropathy with liability to pressure palsies.....	375
Hereditary metabolic storage disorders with neurologic manifestations .....	375
Gaucher disease .....	375
Pompe's disease .....	376
Mitochondrial disorders affecting the nervous system .....	376
Spinal muscular atrophy .....	376
Biomarkers of SMA.....	377
<b>Biomarkers of the aging brain.....</b>	<b>377</b>
Cellular biomarker of aging of the brain .....	377
CSF F2-isoprostanes as biomarker of aging brain .....	377
IL-6 as a biomarker of cognitive impairment with aging .....	378
MRI transverse relaxation rate alteration as biomarker of aging brain.....	378
Protein aggregation as a biomarker of aging brain.....	378
Telomere shortening as a biomarker of aging brain and dementia .....	378
<b>Biomarkers of neurodegenerative disorders .....</b>	<b>379</b>
<b>Biomarkers of dementia .....</b>	<b>379</b>
Biomarkers of vascular dementia .....	380
<b>Biomarkers of Alzheimer's disease .....</b>	<b>380</b>
The ideal biomarker for AD.....	382
Methods for determining biomarkers of AD .....	382
Gene expression patterns in AD .....	382
Magnetic resonance spectroscopy in AD .....	383
MicroRNAs as biomarkers of neurodegenerative disorders .....	383
MRI for biomarkers of AD.....	384
Nanotechnology to measure A $\beta$ -derived diffusible ligands.....	385
PET scanning for biomarkers of AD.....	385
Simultaneous measurement of several biomarkers for AD .....	387
Targeting of chemokine receptor as biomarker for brain imaging.....	387
Biomarkers of AD in CSF .....	388
CSF sulfatide as a biomarker for AD .....	388
CSF Reelin as biomarker of AD.....	388
Monitoring of synthesis and clearance rates of A $\beta$ in the CSF .....	388
Protein biomarkers of AD in CSF .....	389
Tau proteins in CSF .....	390
Tests for the detection of A $\beta$ in CSF.....	390
Tests combining CSF tau and A $\beta$ .....	391
Blood biomarkers of AD .....	392
A serum protein-based algorithm for the detection of AD .....	392
Amyloid precursor protein .....	392
Detection of aggregated misfolded proteins in the blood .....	392



<i>Lipid biomarkers for preclinical detection of AD</i> .....	393
<i>Lymphocyte Proliferation Test</i> .....	393
<i>Metabolomic biomarker profiling</i> .....	393
<i>Plasma protein biomarkers of AD</i> .....	393
<i>Protein kinase C in red blood cells</i> .....	394
Urine tests for AD .....	395
A biomarker-based skin test for AD .....	395
Salivary biomarkers of AD .....	395
Applications of biomarkers of AD .....	396
<i>Biomarker changes in autosomal dominantly inherited AD</i> .....	396
<i>Correlation of imaging biomarkers with CSF biomarkers of AD</i> .....	396
<i>Genetic tests for AD</i> .....	396
<i>Humanin as a biomarker as well as neuroprotective in AD</i> .....	397
<i>Plasma biomarkers of drug response in AD</i> .....	397
<i>PredictAD project</i> .....	398
<i>TOMM40 gene and risk of AD</i> .....	398
<i>Use of biomarkers to predict AD in patients with MCI</i> .....	398
Concluding remarks about biomarkers for AD and future prospects .....	399
<b>Biomarkers of Parkinson's disease</b> .....	<b>400</b>
Autoantibodies as biomarkers of PD .....	401
Biomarkers of PD based on gene expression in blood .....	401
Cardiac denervation as a biomarker of PD .....	401
Caffeine levels in blood .....	402
Genetic biomarkers of PD .....	402
Imaging biomarkers of PD .....	403
Metabolic brain networks as biomarkers .....	403
Metabonomic biomarker profile for diagnosis and monitoring of PD .....	404
Protein biomarkers of PD .....	404
<i>P11 protein as a biomarker of depression in PD</i> .....	404
Serum vitamin D as a biomarker of PD .....	405
Biomarkers of prodromal PD .....	405
Future needs for biomarkers of PD .....	405
<b>Biomarkers of Huntington's disease</b> .....	<b>406</b>
Genetic biomarker of HD progression .....	407
Quantitative MRI measurement of brain atrophy as biomarker of HD .....	408
Metabolic networks as biomarkers of preclinical Huntington disease .....	408
<b>Biomarkers of Wilson's disease</b> .....	<b>408</b>
<b>Biomarkers of amyotrophic lateral sclerosis</b> .....	<b>409</b>
ALS biomarker detection in blood vs CSF .....	410
Biomarkers of neuroinflammation in ALS .....	410
Genetic biomarkers of ALS .....	410
Imaging biomarkers of ALS .....	411
Metabolomic biomarkers of ALS .....	411
Proteomic biomarkers of ALS .....	411
Ideal biomarker of ALS .....	412
Future of biomarkers of ALS .....	412
<b>HIV-1-associated neurocognitive disorders</b> .....	<b>412</b>
Biomarkers of dementia in HIV-1-infected patients .....	413
<b>Biomarkers of autoimmune encephalitis</b> .....	<b>413</b>
<b>Biomarkers of prion diseases</b> .....	<b>413</b>
14-3-3 protein and tTau/P-Tau ratio .....	413
Bioluminescence imaging as a surrogate biomarker of prion infectivity .....	414
miRNAs as biomarkers of prion-induced neurodegeneration .....	414
MRI biomarker of CJD .....	414
Prion protein detection by real-time quaking-induced conversion .....	415
Prions in the urine of patients with variant CJD .....	415
<b>Biomarkers of multiple sclerosis</b> .....	<b>415</b>
Antibodies in multiple sclerosis .....	417
<i>Antibodies to galactocerebroside</i> .....	417
<i>Antibodies to myelin oligodendrocyte glycoprotein</i> .....	417
Brain N-acetylaspartylglutamate as biomarker of cognitive function in MS .....	417
Brain imaging biomarkers of multiple sclerosis .....	418
<i>MRI biomarkers of multiple sclerosis</i> .....	418
<i>Molecular imaging</i> .....	418
Biomarkers of response to therapy of multiple sclerosis .....	419
<i>Biomarkers of response to of interferon <math>\beta</math>-1a</i> .....	419
<i>DNA motifs in the blood as biomarkers of response to treatment</i> .....	419
<i>Gene expression</i> .....	419
<i>Lymphocyte subsets as biomarkers of therapeutic response</i> .....	420
<i>Neurofilaments</i> .....	421
<i>Vitamin D as predictor of activity and progression of MS</i> .....	421

CSF biomarkers in multiple sclerosis.....	421
CSF Cystatin C as a biomarker of multiple sclerosis.....	421
Detecting autoantibodies in multiple sclerosis.....	421
<i>Switch-associated protein 70 antibodies in multiple sclerosis</i> .....	422
Gelsolin as a biomarker of multiple sclerosis.....	422
Matrix metalloproteinases as biomarkers in multiple sclerosis.....	422
Oligoclonal bands as biomarkers of MS.....	423
Serum proteomic pattern analysis in multiple sclerosis.....	423
T cells as biomarkers of multiple sclerosis.....	423
Concluding remarks and future perspective for biomarkers of multiple sclerosis.....	423
<b>Biomarkers of cerebrovascular disorders.....</b>	<b>424</b>
Biomarkers of stroke.....	424
<i>Etiological biomarkers of ischemic stroke</i> .....	426
<i>Brain natriuretic peptide as a biomarker for cardioembolic stroke</i> .....	427
<i>Brain lactate and N-acetylaspartate as biomarkers of stroke</i> .....	427
<i>CCL23 for prediction of stroke patient outcome</i> .....	427
<i>CRP as biomarker of risk of stroke</i> .....	427
<i>CSF biomarkers in acute stroke</i> .....	428
<i>Gene expression in blood following ischemic stroke</i> .....	428
<i>Glutathione S-Transferase-n</i> .....	428
<i>Intercellular adhesion molecule 1 as biomarker of ischemic stroke</i> .....	429
<i>Lp-PLA2 and CRP as biomarkers for stroke</i> .....	429
<i>Matrix metalloproteinase-9</i> .....	429
<i>miRNAs as biomarkers of stroke</i> .....	429
<i>Neuroserpin polymorphisms as a biomarker of stroke</i> .....	429
<i>NMDA receptors as biomarkers of excitotoxicity in stroke</i> .....	430
<i>Nucleosomes as biomarkers of stroke</i> .....	430
<i>PARK7 and nucleoside diphosphate kinase A as biomarkers of stroke</i> .....	430
<i>Visinen-like protein 1</i> .....	431
<i>Biomarker panels for stroke</i> .....	431
<i>Future prospects for biomarkers of stroke</i> .....	431
Biomarkers of cerebral vasospasm.....	432
Biomarkers of intracerebral hemorrhage.....	432
Biomarkers of hypoxic brain damage.....	433
Biomarkers of ischemic brain damage.....	433
D-dimer as a biomarker of cerebral venous thrombosis.....	433
<b>Biomarkers of traumatic brain injury.....</b>	<b>434</b>
Technologies for identification of biomarkers of TBI.....	434
<i>Cerebral microdialysis for study of biomarkers of TBI</i> .....	434
<i>Proteomic technologies for biomarkers of TBI</i> .....	435
<i>Systems biology approach for discovery of biomarkers of TBI</i> .....	436
Biomarkers of TBI.....	436
<i>A<math>\beta</math> as a biomarker of TBI</i> .....	437
<i>CCL11 as a biomarker of chronic traumatic encephalopathy</i> .....	437
<i>Diffusion tensor imaging in TBI</i> .....	437
<i>Glial fibrillary acidic protein as biomarker of TBI</i> .....	437
<i>Hyperphosphorylated axonal neurofilament protein</i> .....	438
<i>IL-6 and nerve growth factor as biomarkers of TBI</i> .....	438
<i>Myelin basic protein</i> .....	438
<i>Neural exosome cargo</i> .....	438
<i>Neurofilament heavy chain</i> .....	438
<i>Serum S100<math>\beta</math> as biomarker of TBI</i> .....	439
<i>SNTF as a biomarker for predicting cognitive decline after mild TBI</i> .....	439
<i>Tau as biomarker of TBI</i> .....	440
<i>Ubiquitin C-terminal Hydrolase-L1</i> .....	440
Biomarkers of inflicted TBI in infants.....	441
Biomarkers of concussion.....	441
Clinical applications of biomarkers of TBI.....	441
<b>Biomarkers of CNS infections.....</b>	<b>442</b>
Biomarkers of bacterial meningitis.....	442
Biomarkers of viral infections of CNS.....	443
<i>Biomarkers of CNS HIV infection</i> .....	443
<i>CSF kynurenic acid level as a biomarker of tick-borne encephalitis</i> .....	443
<i>Serum uric acid levels as biomarker of acute CNS viral infections</i> .....	443
<b>Biomarkers of epilepsy.....</b>	<b>444</b>
Biochemical markers of epilepsy.....	444
Biomarkers of temporal lobe epilepsy.....	445
Biomarkers of drug-resistant epilepsy.....	445
Genetic epilepsies.....	445
Electrophysiological biomarkers of epilepsy.....	445
Imaging biomarkers of epilepsy.....	446

Protein biomarkers of inflammation in epilepsy .....	446
<b>Biomarkers of normal pressure hydrocephalus .....</b>	<b>446</b>
<b>Biomarkers of pseudotumor cerebri.....</b>	<b>447</b>
<b>Biomarkers of retinal disorders.....</b>	<b>447</b>
Biomarkers of age-related macular degeneration .....	447
<b>Biomarkers of sleep disorders.....</b>	<b>448</b>
Biomarker of excessive daytime sleepiness .....	448
Biomarkers of obstructive sleep apnea.....	449
Biomarkers of restless legs syndrome .....	449
<b>Biomarkers of pain.....</b>	<b>450</b>
Biomarkers of disorders with musculoskeletal pain .....	450
Biomarkers of neuropathic pain .....	450
Brain insular glutamate as biomarker of fibromyalgia .....	451
Biomarkers of visceral pain .....	451
Biomarkers of migraine .....	451
<b>Biomarkers of myalgic encephalomyelitis/chronic fatigue syndrome .....</b>	<b>452</b>
<b>Biomarkers of psychiatric disorders.....</b>	<b>453</b>
Anorexia nervosa .....	453
Attention-deficit hyperactivity disorder .....	453
Biomarkers of autism .....	454
<i>Epigenetics of ASD .....</i>	<i>454</i>
<i>Gastrointestinal microbiota disturbances and ASD .....</i>	<i>454</i>
<i>Genetic factors in ASD .....</i>	<i>455</i>
<i>Immune biomarkers of ASD .....</i>	<i>455</i>
<i>Metabolic disturbances in autism.....</i>	<i>455</i>
<i>Neurophysiological biomarkers.....</i>	<i>456</i>
<i>Role of oxidative stress in autism .....</i>	<i>456</i>
<i>Test for ASD based on a 55-gene expression panel .....</i>	<i>456</i>
<i>Umbilical cord biomarkers .....</i>	<i>457</i>
Biomarkers of bipolar disorder .....	457
Biomarkers of depression .....	457
<i>Biochemical biomarkers of depression.....</i>	<i>459</i>
<i>Biomarkers and response to antidepressant treatment.....</i>	<i>459</i>
<i>Cingulate cortex activity and response to antidepressants .....</i>	<i>460</i>
<i>Genetic biomarkers of response to antidepressants .....</i>	<i>460</i>
<i>Inflammatory biomarkers of depression and psychosis.....</i>	<i>460</i>
<i>P11 as a biomarker of depression.....</i>	<i>461</i>
<i>Panels of blood-based biomarkers for diagnosis of MDD .....</i>	<i>461</i>
<i>Plasma metabolomics for diagnosis of MDD .....</i>	<i>461</i>
<i>Post-partum depression .....</i>	<i>461</i>
Biomarkers of posttraumatic stress disorder .....	462
Biomarkers of psychosis .....	463
Biomarkers of schizophrenia .....	463
<i>Biomarkers of abnormalities of visual information processing.....</i>	<i>464</i>
<i>Genetic biomarkers of schizophrenia.....</i>	<i>464</i>
<i>Gene expression analysis of blood for biomarkers of schizophrenia .....</i>	<i>464</i>
<i>Metabolic biomarkers of schizophrenia .....</i>	<i>465</i>
<i>Proteomic studies for biomarkers of schizophrenia .....</i>	<i>465</i>
Biomarkers of suicide .....	465

## **15. Biomarkers of Cardiovascular Disorders ..... 467**

<b>Epidemiology of cardiovascular disease .....</b>	<b>467</b>
<b>Biomarkers of cardiovascular diseases .....</b>	<b>467</b>
Biomarkers of acute myocardial infarction .....	469
Genetic biomarkers of cardiovascular disorders.....	469
<b>Methods for identification of cardiovascular biomarkers.....</b>	<b>471</b>
Application of proteomics for biomarkers of cardiovascular disease.....	471
<i>Targeted MS-based pipeline approach.....</i>	<i>471</i>
<i>Cardiovascular disease biomarker panel.....</i>	<i>472</i>
Detection of biomarkers of myocardial infarction in saliva by a nanobiochip.....	472
Metabolomic technologies for biomarkers of myocardial ischemia .....	472
Imaging biomarkers of cardiovascular disease .....	472
<i>Annexin A5 as an imaging biomarker of cardiovascular disease.....</i>	<i>473</i>
<i>Cardiovascular MRI .....</i>	<i>473</i>
<i>Cardiovascular hybrid imaging .....</i>	<i>473</i>
<i>Myocardial perfusion imaging .....</i>	<i>473</i>
Implantable magnetic biosensors for detecting cardiac biomarkers.....	474
<b>Applications of biomarkers of cardiovascular disease.....</b>	<b>474</b>
Biomarkers for ischemic heart disease and myocardial infarction.....	474
<i>Troponin .....</i>	<i>475</i>
<i>Natriuretic peptide .....</i>	<i>476</i>

<i>Copeptin</i> .....	477
<i>Creatine kinase muscle brain</i> .....	478
<i>miRNAs as biomarkers of acute coronary syndrome</i> .....	478
<i>Myoglobin</i> .....	478
<i>Fatty acid binding protein</i> .....	478
<i>Growth Differentiation Factor-15</i> .....	479
<i>High density lipoprotein 2</i> .....	479
<i>Cripto-1 as a biomarker of myocardial infarction</i> .....	479
<i>Cataract as a biomarker of ischemic heart disease</i> .....	479
<i>Plasma CD93 as a biomarker for coronary artery disease</i> .....	480
<i>Plasma fetuin-A levels and the risk of myocardial infarction</i> .....	480
<i>YKL-40 as an inflammatory biomarker in ischemic heart disease</i> .....	480
<b>Biomarkers of cardiomyopathy</b> .....	480
<i>miRNA biomarkers of peripartum cardiomyopathy</i> .....	480
<i>Takotsubo cardiomyopathy</i> .....	481
<i>Troponin T levels in hypertrophic cardiomyopathy</i> .....	481
<b>Biomarkers of heart failure</b> .....	481
<i>Annexin A5 for prognosis of heart failure</i> .....	481
<i>Angiogenesis biomarkers</i> .....	482
<i><math>\beta</math>-2a protein as a biomarker of heart failure</i> .....	482
<i>Desmin</i> .....	482
<i>Galectin-3 as biomarker of acute heart failure</i> .....	482
<i>G protein-coupled receptor kinase-2 as biomarker of CHF</i> .....	483
<i>KIF6 gene as biomarker of heart failure</i> .....	483
<i>Metabolic biomarkers of heart failure</i> .....	484
<i>miRNA biomarkers of heart failure</i> .....	484
<i>Natriuretic peptide as biomarker of heart failure</i> .....	484
<i>Oxidative stress as biomarker of heart failure</i> .....	485
<i>Future prospects for biomarkers of heart failure</i> .....	485
<b>Biomarkers for atherosclerosis</b> .....	485
<i>9p21-3 locus and coronary atherosclerosis</i> .....	485
<i>Adipocyte enhancer-binding protein 1</i> .....	486
<i>Gene signatures on leucocytes as biomarkers of atherosclerosis</i> .....	486
<i>Ghrelin as a biomarker of atherosclerosis</i> .....	487
<i>Imaging biomarkers of hypercholesterolemia/atherosclerosis</i> .....	487
<i>Inflammatory biomarkers of atherosclerosis</i> .....	487
<i>Lipid-modified proteins as biomarkers of atherosclerosis</i> .....	487
<i>Lp-PLA2 as biomarker of atherosclerotic heart disease</i> .....	487
<i>Metabolomic profile in hypercholesterolemia</i> .....	488
<i>Nitric oxide impairment and atherosclerosis</i> .....	488
<i>Oxygen free radicals as biomarkers of atherosclerosis</i> .....	488
<i>Proteomic profiles of serum inflammatory biomarkers of atherosclerosis</i> .....	488
<b>Biomarkers of coronary heart disease</b> .....	489
<i>Apolipoproteins as risk factors for coronary heart disease</i> .....	489
<i>CRP as biomarker of risk for coronary heart disease</i> .....	489
<i>High level of blood ceramides as a biomarker of CHD</i> .....	490
<i>Impairment of EPCs by oxidative stress as a biomarker of disease</i> .....	490
<i>Role of TNF in acute coronary syndromes</i> .....	491
<i>Serum parathyroid hormone as biomarker of CHD</i> .....	491
<i>Serum stem cell factor as a biomarker of CHD</i> .....	491
<i>VILCAD biomarker score for prediction of long-term mortality in CHD</i> .....	491
<b>Biomarkers for pulmonary arterial hypertension</b> .....	492
<b>Biomarkers of abdominal aortic aneurysm</b> .....	492
<b>Biomarkers of thrombotic disorders</b> .....	494
<i>Biomarkers of arterial thromboembolism</i> .....	494
<i>Nanoparticles as synthetic biomarkers of thrombus formation</i> .....	494
<i>Biomarkers of venous thromboembolism</i> .....	494
<i>BNP and cTnT as biomarkers of outcome in pulmonary embolism</i> .....	494
<i>D-dimer as biomarker of venous thromboembolism</i> .....	495
<i>Molecular biomarkers of venous thromboembolism</i> .....	495
<i>Genetic biomarkers for cardiovascular disease</i> .....	495
<i>Biomarkers of inherited cardiomyopathies</i> .....	495
<i>Gene mutations in pulmonary arterial hypertension</i> .....	495
<i>Gene variant as a risk factor for sudden cardiac death</i> .....	496
<i>Genetic biomarkers of early onset myocardial infarction</i> .....	496
<i>Genetic biomarkers of atherosclerosis</i> .....	496
<i>IL-1 gene polymorphism as biomarker of cardiovascular disease</i> .....	497
<i>IL-6R signaling pathway and coronary heart disease</i> .....	497
<i>Kallikrein gene mutations in cardiovascular disease</i> .....	497
<i>Kallikrein gene and essential hypertension</i> .....	498
<i>Mutations in the low density lipoprotein receptor gene</i> .....	498

<i>Mutations within several genes that code for ion channel</i> .....	498
<i>Polymorphisms of the eNOS gene and angina pectoris</i> .....	499
<i>Lipoprotein (a) genetics</i> .....	499
<i>Polymorphisms in the apolipoprotein C gene</i> .....	499
<i>Polymorphisms in the apolipoprotein E gene</i> .....	500
<i>Polymorphism in the angiotensinogen gene</i> .....	500
Multiple biomarkers for prediction of death from cardiovascular disease .....	500
<b>Role of biomarkers in the management of cardiovascular disease</b> .....	<b>501</b>
Biomarkers in the diagnosis/prognosis of myocardial infarction .....	501
Biomarkers for prevention of cardiovascular disease .....	501
C reactive protein as biomarker of response to statin therapy .....	503
C125 as biomarker for stratification in heart disease .....	503
HSP72 and eNOS as biomarkers of cardioprotective effect of HBO .....	504
Multimarker panel for prognosis in chronic heart failure .....	504
Molecular signature analysis in management of cardiovascular diseases.....	504
Presage ST2 Assay .....	505
Role of circulating biomarkers and mediators of cardiovascular dysfunction .....	505
Use of protein biomarkers for monitoring acute coronary syndromes .....	505
Use of biomarkers for prognosis of recurrent atrial fibrillation .....	506
Use of multiple biomarkers for monitoring of cardiovascular disease .....	506
Use of biomarkers in the management of peripheral arterial disease.....	506
Use of biomarkers in the management of hypertension .....	507
<b>Systems approach to cardiovascular biomarker research</b> .....	<b>507</b>
<b>16. Biomarkers of Pulmonary Diseases</b> .....	<b>509</b>
<b>Introduction</b> .....	<b>509</b>
Association of biomarkers of inflammation with lung function in the elderly .....	509
Biomarkers of oxidative stress in lung diseases.....	510
Biomarkers of community-acquired pneumonia.....	510
Biomarkers of acute lung injury and respiratory distress syndrome .....	510
<i>Cytokine/chemokine biomarkers of SARS</i> .....	510
<i>Plasma biomarkers related to inflammation</i> .....	511
<i>Urinary NO as biomarker</i> .....	511
Biomarkers of interstitial lung disease .....	511
<i>Pulmonary surfactant proteins as biomarkers for lung diseases</i> .....	511
<i>Serum KL-6 as biomarker of interstitial lung disease</i> .....	512
Biomarkers of chronic obstructive pulmonary disease .....	512
<i>Alpha1-antitrypsin gene polymorphisms predisposing to emphysema</i> .....	512
<i>Biomarkers of extracellular matrix turnover in COPD</i> .....	513
<i>Biomarkers of lung failure in COPD</i> .....	513
<i>BNP as a biomarker of chronic pulmonary disease</i> .....	513
<i>Chromagranin A (CgA) as biomarker of airway obstruction in smokers</i> .....	514
<i>C-reactive protein as a biomarker of COPD</i> .....	514
<i>Gene expression profile in peripheral blood of patients with COPD</i> .....	514
<i>Hyperuricemia as a biomarker of early mortality in COPD</i> .....	514
<i>Increased expression of PIGF as a biomarker of COPD</i> .....	514
Biomarkers of asthma.....	515
<i>Biomarker for rhinovirus-induced asthma exacerbation</i> .....	515
<i>Biomarkers for predicting response to corticosteroid therapy</i> .....	515
<i>Comparison of biomarkers of asthma and COPD</i> .....	515
<i>Cytokines as biomarkers of asthma severity</i> .....	516
<i>Exhaled NO as a biomarker of asthma</i> .....	516
<i>Endothelin-1 in exhaled breath as biomarker of asthma</i> .....	517
<i>IgE as guide to dosing of omalizumab for asthma</i> .....	517
<i>Periostin as a biomarker for treatment of asthma with lebrikizumab</i> .....	517
Biomarkers of cystic fibrosis .....	518
<b>17. Biomarkers in Gynecology and Obstetrics</b> .....	<b>519</b>
<b>Introduction</b> .....	<b>519</b>
<b>Biomarkers of menopause</b> .....	<b>519</b>
<b>Biomarkers of premenstrual dysphoric disorder</b> .....	<b>519</b>
<b>Biomarkers of endometriosis</b> .....	<b>520</b>
<b>Biomarkers of preeclampsia</b> .....	<b>520</b>
Pathogenesis of preeclampsia .....	520
Metabolomic biomarkers in urine in preeclampsia.....	521
Protein biomarker of preeclampsia in urine.....	521
Protein biomarkers of preeclampsia in CSF .....	522
Protein HtrA1 as a biomarker for preeclampsia .....	522
Placental growth factor as a biomarker for preeclampsia .....	523
sFlt1 and soluble endoglin as biomarkers of preeclampsia .....	523
RNA biomarkers.....	523

Genes associated with preeclampsia .....	524
<b>Biomarkers of premature birth .....</b>	<b>524</b>
Proteomic biomarkers of premature birth .....	524
<b>Biomarkers of oxidative stress in complicated pregnancies .....</b>	<b>525</b>
<b>Fetal biomarkers in maternal blood .....</b>	<b>525</b>
<b>Metabolic biomarkers of prenatal disorders in the mother .....</b>	<b>526</b>
<b>18. Biomarkers &amp; Personalized Medicine .....</b>	<b>527</b>
<b>Introduction.....</b>	<b>527</b>
<b>Pharmacogenetics.....</b>	<b>527</b>
Biomarkers and pharmacogenetics .....	528
<b>Pharmacogenomics .....</b>	<b>529</b>
<b>Pharmacoproteomics .....</b>	<b>530</b>
Single cell proteomics for personalized medicine .....	530
<b>Role of biomarkers in development of personalized drugs .....</b>	<b>531</b>
Metabolomic biomarker-based drug discovery.....	531
Use of biomarkers for developing MAb therapy in oncology .....	531
<b>Biomarker tests for molecularly targeted therapies .....</b>	<b>532</b>
<b>Biobanking, biomarkers and personalized medicine in EU .....</b>	<b>533</b>
<b>Bioinformatics to sort biomarker data for personalized medicine .....</b>	<b>534</b>
<b>Biomarkers for monitoring response to therapy .....</b>	<b>535</b>
<b>Drug rescue by biomarker-based personalized medicine .....</b>	<b>535</b>
<b>Future role of biomarkers in personalized medicine .....</b>	<b>536</b>
<b>19. Biomarkers and Regulatory issues .....</b>	<b>537</b>
<b>Introduction.....</b>	<b>537</b>
<b>Biomarker validation.....</b>	<b>537</b>
FDA criteria for a valid biomarker .....	537
FDA letter of support for biomarkers.....	539
Role of NIST in validation of cancer biomarkers .....	540
Quality specifications for BNP and NT-proBNP as cardiac biomarker assays .....	540
National Biomarker Development Alliance .....	540
<b>FDA perspective of biomarkers in clinical trials .....</b>	<b>541</b>
<b>FDA and predictive medicine.....</b>	<b>542</b>
<b>Biomarkers and FDA's Voluntary Genomic Data Submission .....</b>	<b>543</b>
<b>Role of imaging biomarkers in approval of drugs.....</b>	<b>543</b>
<b>Regulatory oversight of biomarker tests for targeted therapies .....</b>	<b>544</b>
<b>FDA and biomarkers.....</b>	<b>544</b>
FDA consortium linking genetic biomarkers to serious adverse events .....	544
Oncology Biomarker Qualification Initiative .....	545
Critical Path Initiative .....	545
Predictive Safety Testing Consortium.....	547
The 21st Century Cures Act and biomarkers .....	547
From validated biomarker assay to a clinical laboratory diagnostic .....	548
Fast Path programs .....	549
Regulatory challenges in the biomarker field.....	549
FDA requirements of biomarkers and companion diagnostics .....	550
<b>20. References.....</b>	<b>551</b>

## Tables

Table 1-1: Historical landmarks in discovery and development of biomarkers .....	30
Table 1-2: Classification of biomarkers .....	30
Table 1-3: Terminology of clinically relevant biomarkers of disease .....	32
Table 1-4: Autoimmune disorders under study for autoantibodies as predictors .....	42
Table 1-5: Comparison of various types of biomarkers .....	42
Table 1-6: Various "omics" technologies for discovery of biomarkers .....	44
Table 1-7: Role of biomarkers in translational medicine .....	45
Table 2-1: Classification of methods of gene expression analysis .....	48
Table 2-2: Comparison of proteomic profiling technologies for discovery of biomarkers .....	75
Table 2-3: Companies involved in developing molecular imaging .....	85
Table 3-1: Applications of biochip/microarray technology in relation to biomarkers .....	109
Table 4-1: Companies using metabolomics for drug discovery .....	123
Table 4-2: Biomarker-based drug development at major pharmaceutical companies .....	124
Table 4-3: Causes of failures in clinical trials and their reduction by use of biomarkers .....	127
Table 5-1: Metabolic biomarkers of inflammatory diseases .....	141
Table 5-2: Oxidized phospholipids as biomarkers of various diseases .....	142
Table 5-3: Examples of biomarkers common to multiple diseases .....	156

Table 5-4: Examples of use of biomarkers in animal health .....	158
Table 6-1: Biomarkers of diabetes mellitus .....	162
Table 7-1: Biomarkers of Sjögren syndrome .....	178
Table 8-1: miRNAs deregulated in rheumatoid arthritic tissues .....	184
Table 8-2: Classification of inflammatory biomarkers in osteoarthritis.....	187
Table 9-1: Biomarkers of sepsis.....	196
Table 11-1: Biomarkers of aging.....	213
Table 12-1: Nutritional biomarkers.....	224
Table 13-1: Desirable characteristics of biomarkers for cancer.....	231
Table 13-2: Types of cancer biomarkers .....	233
Table 13-3: A classification of molecular diagnostic methods in cancer .....	240
Table 13-4: Cancer biomarkers used for diagnosis and therapy .....	270
Table 13-5: Novel biomarkers of prognosis in cancer treatment.....	276
Table 13-6: Biomarkers of brain tumors .....	284
Table 13-7: Biomarkers of breast cancer .....	292
Table 13-8: miRNA associated with breast cancer .....	301
Table 13-9: Biomarkers of colorectal cancer.....	311
Table 13-10: Biomarkers of lung cancer .....	325
Table 13-11: Classification of biomarkers of melanoma .....	334
Table 13-12: Biomarkers of nasopharyngeal carcinoma and potential applications .....	335
Table 13-13: Biomarkers of ovarian cancer .....	338
Table 13-14: Classification of biomarkers of pancreatic cancer .....	343
Table 13-15: Biomarkers of prostate cancer.....	348
Table 14-1: Biomarkers of cerebral metabolism .....	367
Table 14-2: Classification of biomarkers of Alzheimer disease in blood and CSF.....	380
Table 14-3: Characteristics of an ideal biomarker for Alzheimer disease .....	382
Table 14-4: miRNA expression in neurodegenerative diseases .....	383
Table 14-5: Biomarkers of Parkinson disease .....	400
Table 14-6: Biomarkers of Huntington disease.....	407
Table 14-7: Classification of biomarkers of amyotrophic lateral sclerosis.....	409
Table 14-8: Biomarkers of multiple sclerosis .....	416
Table 14-9: Gene expression as biomarker of response to interferon- $\beta$ in multiple sclerosis .....	420
Table 14-10: Biomarkers of stroke .....	425
Table 14-11: Etiological blood biomarkers of ischemic strokes due to large artery atherosclerosis .....	426
Table 14-12: Biomarkers of traumatic brain injury .....	436
Table 14-13: Biomarkers of epilepsy .....	444
Table 14-14: Biomarkers of autism spectrum disorder.....	454
Table 14-15: Biomarkers of response to antidepressant treatment.....	459
Table 14-16: Biomarkers of posttraumatic stress disorder.....	462
Table 15-1: Classification of biomarkers for cardiovascular diseases.....	468
Table 15-2: Genes that cause cardiovascular diseases.....	470
Table 15-3: Biomarkers of abdominal aortic aneurysm .....	493
Table 15-4: Biomarkers for cardiovascular disease risk prediction .....	501
Table 16-1: Biomarkers of pulmonary diseases.....	509
Table 18-1: Pharmacogenetic vs. pharmacogenomic studies .....	528
Table 18-2: Applications of pharmacoproteomic biomarkers in personalized medicine.....	530
Table 19-1: Issued letters of support for biomarkers by the FDA.....	539
Table 19-2: Drugs requiring biomarker/companion diagnostic information in the label.....	550

## Figures

Figure 1-1: Relation of biomarkers to other technologies and healthcare.....	45
Figure 1-2: Role of biomarkers in monitoring of diseases .....	46
Figure 2-1: The central role of spectrometry in proteomics .....	57
Figure 2-2: Selected reaction monitoring workflow for verification of biomarkers .....	71
Figure 4-1: Role of biomarkers in drug discovery and development process .....	113
Figure 4-2: Onion-peel model of biomarker development.....	128
Figure 5-1: Diseases associated with myositis autoantibodies.....	157
Figure 6-1: Plasma lipids in metabolic syndrome.....	168
Figure 8-1: $\beta$ -CrossLaps bone resorption biomarker assay .....	190
Figure 13-1: Role of proteomics in the discovery of cancer biomarkers .....	247
Figure 13-2: Nanovesicles for detection of cancer biomarkers.....	263
Figure 13-3: Nanowire biosensor for cancer diagnosis .....	263
Figure 13-4: Cancer biomarker development and validation .....	363
Figure 14-1: Discovery and application of biomarkers in neurological diseases .....	365
Figure 14-2: MRI in Creutzfeldt-Jakob disease .....	415
Figure 14-3: A scheme of pathogenesis of MDD with relevant biomarkers .....	459
Figure 15-1: Biomarkers of acute myocardial infarction related to pathophysiology .....	469
Figure 18-1: Role of pharmacogenetic biomarkers in personalized medicine .....	529
Figure 18-2: Workflow for developing metabolomics-based biomarkers for personalized treatment ....	531

Figure 18-3: Impact of biomarkers on personalized medicine .....	536
Figure 19-1: Stages and timelines of biomarker discovery, development and marketing .....	537
Figure 19-2: Biomarker qualification pilot process at the FDA .....	539
Figure 19-3: From a validated biomarker assay to a clinical laboratory diagnostic .....	548